BACKGROUND: To evaluate the outcomes of radiation therapy treatment of male patients with breast cancer in our single institutional cohort and discover possible adverse prognostic factors. METHODS: We retrospectively evaluated 42 male patients (median age 55; range 33-77 years) with breast cancer. Patients were irradiated postoperatively in 2 Gy/fraction/day to chest wall +/- lymphatics. RESULTS: Median follow-up was 29 months. Eleven patients had neoadjuvant and 36 patients had adjuvant Adriamycin-based chemotherapy. Nine patients (21%) had local or regional, two (5%) had distant, and one (2.5%) had both local and distant disease at the time of analysis. The actuarial five-year Overall Survival (OS) was 77%, whereas the actuarial five-year Disease-Free (DFS), Locoregional Recurrence-free (LRRFS), and Distant Metastases-Free (DMFS) survival rates were 45%, 69% and 66%, respectively. Univariate analysis of variables, including patient characteristics, treatment modalities and factors, and tumor characteristics, failed to show an association with LRRFS and DFS except percent positive nodal involvement > or = 30% and 50%. CONCLUSION: Though radiotherapy seems quite effective in reducing local recurrence, we have revealed that male breast cancer patients in our cohort with extensive nodal involvement (PPNI >30% and 50%) appeared not to have had a significant benefit from postmastectomy irradiation and adjuvant CMF-based chemotherapy.
BACKGROUND: To evaluate the outcomes of radiation therapy treatment of male patients with breast cancer in our single institutional cohort and discover possible adverse prognostic factors. METHODS: We retrospectively evaluated 42 male patients (median age 55; range 33-77 years) with breast cancer. Patients were irradiated postoperatively in 2 Gy/fraction/day to chest wall +/- lymphatics. RESULTS: Median follow-up was 29 months. Eleven patients had neoadjuvant and 36 patients had adjuvant Adriamycin-based chemotherapy. Nine patients (21%) had local or regional, two (5%) had distant, and one (2.5%) had both local and distant disease at the time of analysis. The actuarial five-year Overall Survival (OS) was 77%, whereas the actuarial five-year Disease-Free (DFS), Locoregional Recurrence-free (LRRFS), and Distant Metastases-Free (DMFS) survival rates were 45%, 69% and 66%, respectively. Univariate analysis of variables, including patient characteristics, treatment modalities and factors, and tumor characteristics, failed to show an association with LRRFS and DFS except percent positive nodal involvement > or = 30% and 50%. CONCLUSION: Though radiotherapy seems quite effective in reducing local recurrence, we have revealed that male breast cancerpatients in our cohort with extensive nodal involvement (PPNI >30% and 50%) appeared not to have had a significant benefit from postmastectomy irradiation and adjuvant CMF-based chemotherapy.
Authors: R S Sverdlov; I Barshack; R B Bar Sade; R G Baruch; G Hirsh-Yehezkel; E Dagan; M Feinmesser; A Figer; E Friedman Journal: Genet Test Date: 2000
Authors: Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: S Eva Singletary; Craig Allred; Pandora Ashley; Lawrence W Bassett; Donald Berry; Kirby I Bland; Patrick I Borgen; Gary Clark; Stephen B Edge; Daniel F Hayes; Lorie L Hughes; Robert V P Hutter; Monica Morrow; David L Page; Abram Recht; Richard L Theriault; Ann Thor; Donald L Weaver; H Samuel Wieand; Frederick L Greene Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544